Cough Syrup Responsible For Over 36 Deaths

Pakistani authorities are investigating allegations that cough syrup has killed at least three dozen people, a government official has announced, making this the second time in recent months that medicine is suspected of causing multiple deaths.

The deaths from the cough syrup occurred in the eastern city of Gujranwala and nearby villages, said local official Abdul Jabbar Shaheen.  Another 54 people thought to have consumed the syrup are also being treated at city hospitals. Officials believe the victims drank the syrup to get high, he said.

According to BBC, tests show the victims’ stomachs contained dextromethorphan, a synthetic morphine derivative used in cough syrup that can have mind-altering effects if consumed in large quantities, said Shaheen. Investigators are trying to determine if the victims drank too much syrup, or whether there was a problem with the medicine itself, he said.

In recent years, more people in Pakistan have become hooked on sedatives and non-conventional drugs like cough syrups, pain killers and anti-allergens.

Syed Zulfiqar Hussain runs the NGO Against Narcotics in Lahore, and says the true number of such addicts is in the millions, “because there is no restriction, one can go and buy anything, it’s so simple. On the other hand regular drugs are expensive and difficult to get.”

The medical superintendent of the District Headquarters Hospital in Gujranwala has said that doctors “do not prescribe such cough syrups; nor do patients use them on their own for cough suppression”.

“Only branded cough syrups of well-reputed multinational companies are given to patients.”

Whether it is the easy availability of synthetic drugs, their open sale in any quantity, or a fault with the raw material or production process, the accusation is that the relevant government departments are not doing their job.

Punjab’s health director Dr Cheema is shifting responsibility onto the Drug Regulatory Authority, created only a few months ago at the federal level.

He says its primary responsibility is to check imports of raw materials and the production of medicines, but that the Punjab government will also take action to prevent any such incident in the future.

“We will not limit ourselves to just these two companies; we will take stern action against all local non-branded companies that are playing with human lives,” he said.

Psychologist Dr Riaz Bhatti says the deaths in Lahore and Gujranwala “have once again proven the fact that there is no health system in the country; things are moving on their own”.

“There are so many crises, law and order situation is bad, life is cheap; people are so frustrated that they are looking for escape, and synthetic drugs provide them with one. But they mix different drugs, it makes them lethal.”

Twenty-three people died in the nearby city of Lahore in November after drinking bad cough syrup sold under the brand name Tyno. They were also described at the time as people who consumed the drug to get high.

Shaheen said the cough syrup involved in the incidents in and around Gujranwala was not sold under a single brand. He said some people in the city make cough syrup to sell specifically to drug addicts, and officials are trying to arrest them.

Officials temporarily closed one Lahore-based pharmaceutical company whose cough syrup was found in the possession of some affected in Gujranwala. They are investigating whether it caused any of the deaths, said Shaheen.

You May Also Like


  • This field is for validation purposes and should be left unchanged.

, , ,

No comments yet.

Leave a Reply

  • This field is for validation purposes and should be left unchanged.
Latest Drug Injury News

Paxil Possibly Linked To Breast Cancer Risk

Cancer researchers from the City of Hope National Medical Center announced a possible link between Paxil and breast cancer. Research focused on Paxil’s estrogen effect Researchers found that Paxil has a weak estrogen effect that could increase women’s breast cancer risks. According to lead author and chairman of City of Hope’s Department of Cancer and […]

Big Pharma under Fire for Kickbacks to Docs

Trust and honesty are the cornerstones to a doctor-patient relationship. With so many doctors receiving financial incentives to use certain medications or medical devices, patients need to know if money drives the decision making process. Doctors are required to disclose potential financial conflicts to each other at conferences, but there currently is no law forcing […]

Dietary Supplements Damage Liver

A recent study revealed a significant increase in liver damage related to dietary supplements. The study, conducted by a national network of liver specialists, found a 13% increase in serious liver damage over a 10 year span. Some of these patients required liver transplants and some have even died due to liver failure. Authors of […]

FDA Advisory Committee Supports Approval of Gilead’s HIV Reducing Drug

The pharmaceutical industry may be on the verge of one of the greatest breakthrough’s that this generation has ever seen.

U.S. Health Regulators Issue New Restrictions For Gilenya, Novartis AG’s’ Multiple Sclerosis Pill

In December 2011, the FDA issued a Drug Safety Communication concerning a patient with multiple sclerosis (MS) who died within 24 hours of taking the first dose of Gilenya (fingolimod).

Latest Medical Device Injury News

Report Raises Concerns Over Heart Defibrillator Leads

The Food and Drug Administration (FDA) has just announced that they received a report that a St. Jude Durata cardiac defibrillator lead conductor became externalized; meaning the wire carrying electricity from the heart defibrillator to the heart was exposed through its insulation, a potentially dangerous and life-threatening defect.

HeartSine Class 1 Defibrillator Recall

HeartSine sent out a letter to customers in September, warning that the defibrillators may intermittently turn on and off, eventually depleting the battery.

FDA Medical Device Approval Based On Little Evidence

More than half of the high-risk cardiovascular devices approved in the past decade had no supporting active control data.

St. Jude Medical Gets FDA Warning

St. Jude Medical Inc. said it received a FDA warning about manufacturing and quality-control problems at its Sylmar, California, plant.

Hospira Still Facing Manufacturing And Regulatory Issues

Hospira has sent out 11 device notifications so far in 2013, including recall and device corrections. The company also said it sent notices to customers about some of its infusion pumps that had to either be recalled, fixed or adjusted.